These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 20375661)

  • 1. Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice.
    Sitbon O; Hoeper MM; Simonneau G
    Curr Opin Pulm Med; 2010 May; 16 Suppl 1():S21-6. PubMed ID: 20375661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical worsening in trials of pulmonary arterial hypertension: results and implications.
    Galiè N; Simonneau G; Barst RJ; Badesch D; Rubin L
    Curr Opin Pulm Med; 2010 May; 16 Suppl 1():S11-9. PubMed ID: 20375660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endpoints in pulmonary arterial hypertension: the role of clinical worsening.
    Peacock A; Keogh A; Humbert M
    Curr Opin Pulm Med; 2010 May; 16 Suppl 1():S1-9. PubMed ID: 20375659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspective on the optimal endpoints for pulmonary arterial hypertension trials.
    Rubin L; Simonneau G
    Curr Opin Pulm Med; 2010 May; 16 Suppl 1():S43-6. PubMed ID: 20375664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of endpoints in the pediatric population: congenital heart disease and idiopathic pulmonary arterial hypertension.
    Haworth SG; Beghetti M
    Curr Opin Pulm Med; 2010 May; 16 Suppl 1():S35-41. PubMed ID: 20375663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
    Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical treatment of pulmonary arterial hypertension.
    Adamali H; Gaine SP; Rubin LJ
    Semin Respir Crit Care Med; 2009 Aug; 30(4):484-92. PubMed ID: 19634087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Look--but also listen! ReQuest: an essay on a new validated scale to assess the outcome of GERD treatment.
    Bardhan KD; Berghöfer P
    Digestion; 2007; 75 Suppl 1():87-100. PubMed ID: 17489037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Just Another Statistic".
    Machtay M; Glatstein E
    Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower esophageal sphincter injections for the treatment of gastroesophageal reflux disease.
    Watson TJ; Peters JH
    Thorac Surg Clin; 2005 Aug; 15(3):405-15. PubMed ID: 16104131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exercise as an end-point in pulmonary hypertension trials.
    McCullagh B; Girgis RE
    Int J Clin Pract Suppl; 2010 Jan; (165):4-6. PubMed ID: 19958394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endpoints for assessing drug activity in clinical trials.
    Pazdur R
    Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension.
    Ghofrani HA; Wilkins MW; Rich S
    Circulation; 2008 Sep; 118(11):1195-201. PubMed ID: 18779455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis.
    Distler O; Behrens F; Pittrow D; Huscher D; Denton CP; Foeldvari I; Humbert M; Matucci-Cerinic M; Nash P; Opitz CF; Rubin LJ; Seibold JR; Furst DE;
    Arthritis Rheum; 2008 Jun; 59(6):867-75. PubMed ID: 18512721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease.
    Coghlan JG; Pope J; Denton CP
    Curr Opin Pulm Med; 2010 May; 16 Suppl 1():S27-34. PubMed ID: 20375662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.